NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Healthcare Biotechnology

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.

TSXV:NGEN - Post by User

NervGen Pharma Corp

Bullboard Posts

Post by Layth1990on Jan 20, 2020 12:43pm

413 Views

Post# 30573802

multiple sclerosis

I haven't get any share in this I'm just hoping it goes down to 2$ and I will load my boat. I'm 29 and I have Ms .There is 1M people with ms in Us and 0.5M in Canada. Remyelinating is a dream for people who have demyelination disease like Ms. if this turns worthy it will be traded in thousands.

Bullboard Posts

@ the Bell: TSX advances to start off Christmas trading week